A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies (CAMELLIA)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Hu5F9 G4 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms CAMELLIA
- 10 Aug 2017 Planned number of patients changed from 30 to 40.
- 10 Aug 2017 Planned End Date changed to 1 Aug 2018.
- 10 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.